 Mallinckrodt plc NYSE: MNK, a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration FDA voted to recommend approval for its investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 HRS-1 8 yes; 7 no. HRS-1 is an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 Terlipressin is an investigational agent being evaluated for the treatment of HRS-1 in the U.S., and its safety and effectiveness have not yet been established by the FDA. 